Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.

SAN DIEGO — Patients with multiple myeloma who receive intravenous immunoglobulin (IVIG) prophylaxis during treatment with teclistamab have fewer infections and better overall survival compared with ...

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival, according to a study published online Jan. 2 in Blood.

Your survival rate for multiple myeloma is likely higher in earlier stages. Younger people often have better outcomes due to their resilience to intensive treatments. Advances in treatment have ...

Success is no longer just about prolonging survival, but about enabling patients to live well after cancer, with fewer ...

Patient-reported physical function scores are significant predictors of survival and adverse events in multiple myeloma treatment. Physical function has a stronger correlation with patient outcomes ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Please provide your email address to receive an email when new articles are posted on . White patients with multiple myeloma and diabetes experienced worse OS compared with their Black counterparts.

SALT LAKE CITY- Researchers with Huntsman Cancer Institute at the University of Utah and collaborators from 17 other institutions have found that multiple myeloma patients with a genetic variation in ...

The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...

The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.